| 发明名称 | Formulation of human antibodies for treating TNF-α associated disorders | ||
| 摘要 | A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | ||
| 申请公布号 | US8802102(B2) | 申请公布日期 | 2014.08.12 |
| 申请号 | US201414147287 | 申请日期 | 2014.01.03 |
| 申请人 | AbbVie Biotechnology Ltd. | 发明人 | Krause Hans-Juergen;Baust Lisa;Dickes Michael |
| 分类号 | A61K39/395;C07K16/24;C07K14/525;A61K9/19;A61K47/10;A61K9/00;A61K47/26;A61K47/22;A61K47/18;A61K47/12 | 主分类号 | A61K39/395 |
| 代理机构 | Ropes & Gray LLP | 代理人 | Ropes & Gray LLP ;Haley, Jr. James F.;Li Z. Ying |
| 主权项 | 1. A stable liquid aqueous pharmaceutical formulation comprising (a) a human IgG1 anti-human Tumor Necrosis Factor alpha (TNFα) antibody, or an antigen-binding portion thereof, at a concentration of 45 to 105 mg/ml, (b) a polyol, (c) a polysorbate at a concentration of 0.1 to 10 mg/ml, and (d) a buffer system comprising succinate and having a pH of 4.5 to 7.0, wherein the antibody comprises the light chain variable region and the heavy chain variable region of D2E7. | ||
| 地址 | Hamilton BM | ||